866-997-4948(US-Canada Toll Free)

Biomay AG - Product Pipeline Review - 2015

Published By :

Global Markets Direct

Published Date : Apr 2015

Category :


No. of Pages : 31

Global Markets Directs, Biomay AG Product Pipeline Review 2015, provides an overview of the Biomay AGs pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Biomay AGs, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.


  • The report provides brief overview of Biomay AG including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Biomay AGs human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the products developmental history and major milestones 
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement 
  • Latest news and deals relating to the Biomay AGs pipeline products
Reasons to buy

  • Evaluate Biomay AGs strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Biomay AG in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Biomay AGs R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Biomay AG and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Biomay AG
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Biomay AG and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues
Table of Contents

Table of Contents 2

List of Tables 4
List of Figures 4
Biomay AG Snapshot 5
Biomay AG Overview 5
Key Information 5
Key Facts 5
Biomay AG - Research and Development Overview 6
Key Therapeutic Areas 6
Biomay AG - Pipeline Review 8
Pipeline Products by Stage of Development 8
Pipeline Products - Monotherapy 9
Pipeline Products - Out-Licensed Products 10
Out-Licensed Products/Combination Treatment Modalities 11
Biomay AG - Pipeline Products Glance 12
Biomay AG - Clinical Stage Pipeline Products 12
Phase II Products/Combination Treatment Modalities 12
Phase I Products/Combination Treatment Modalities 13
Biomay AG - Early Stage Pipeline Products 14
Preclinical Products/Combination Treatment Modalities 14
Biomay AG - Drug Profiles 15
BM-32 15
Product Description 15
Mechanism of Action 15
R&D Progress 15
fish hypoallergenic vaccine 17
Product Description 17
Mechanism of Action 17
R&D Progress 17
grass allergy vaccine 18
Product Description 18
Mechanism of Action 18
R&D Progress 18
BM-31 19
Product Description 19
Mechanism of Action 19
R&D Progress 19
BM-34 20
Product Description 20
Mechanism of Action 20
R&D Progress 20
BM-35 21
Product Description 21
Mechanism of Action 21
R&D Progress 21
BM-36 22
Product Description 22
Mechanism of Action 22
R&D Progress 22
Japanese cedar hypoallergenic vaccine 23
Product Description 23
Mechanism of Action 23
R&D Progress 23
ragweed hypoallergenic vaccine 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
Biomay AG - Pipeline Analysis 25
Biomay AG - Pipeline Products by Route of Administration 25
Biomay AG - Pipeline Products by Molecule Type 26
Biomay AG - Recent Pipeline Updates 27
Biomay AG - Dormant Projects 28
Biomay AG - Locations And Subsidiaries 29
Head Office 29

Appendix 30
Methodology 30
Coverage 30
Secondary Research 30
Primary Research 30
Expert Panel Validation 30
Contact Us 30
Disclaimer 31

List of Table

Biomay AG, Key Information 5
Biomay AG, Key Facts 5
Biomay AG - Pipeline by Indication, 2015 7
Biomay AG - Pipeline by Stage of Development, 2015 8
Biomay AG - Monotherapy Products in Pipeline, 2015 9
Biomay AG - Out-Licensed Products in Pipeline, 2015 10
Biomay AG - Out-Licensed Products/ Combination Treatment Modalities, 2015 11
Biomay AG - Phase II, 2015 12
Biomay AG - Phase I, 2015 13
Biomay AG - Preclinical, 2015 14
Biomay AG - Pipeline by Route of Administration, 2015 25
Biomay AG - Pipeline by Molecule Type, 2015 26
Biomay AG - Recent Pipeline Updates, 2015 27
Biomay AG - Dormant Developmental Projects,2015 28

List of Chart

Biomay AG - Pipeline by Top 10 Indication, 2015 7
Biomay AG - Pipeline by Stage of Development, 2015 8
Biomay AG - Monotherapy Products in Pipeline, 2015 9
Biomay AG - Out-Licensed Products in Pipeline, 2015 10
Biomay AG - Pipeline by Top 10 Molecule Type, 2015 26

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *